OMGA insider filings
Omega Therapeutics, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2024-12-05. Screen OMGA transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for OMGA between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Omega Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2024-12-05 | 4 | Mehrotra Ravi — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2024-11-26 | 4 | Nelson Jennifer Ann — Chief Scientific Officer | Grant/award (A): 110,000 (derivative) @ $0 | EDGAR |
| 2024-11-15 | 4 | Certel Kaan — See Remarks, Director | Grant/award (A): 340,000 (derivative) @ $0 | EDGAR |
| 2024-10-04 | 4 | Rosiello Robert L. — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | Levy Elliott M. — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | Werner Michelle C — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | Boehm Rainer J. — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | Young Richard A — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | Szela Mary T — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | Kender Richard N — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | MENDLEIN JOHN — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | SCHADE CHRISTIAN S — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-05-31 | 4 | Certel Kaan — Chief Business Officer | Grant/award (A): 220,000 (derivative) @ $0 | EDGAR |
| 2024-02-09 | 4 | McCauley Thomas — Chief Scientific Officer | Grant/award (A): 125,000 (derivative) @ $0 · Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2024-02-09 | 4 | Karande Mahesh — President and CEO, Director | Grant/award (A): 209,551 (derivative) @ $0 · Grant/award (A): 314,326 (derivative) @ $0 | EDGAR |
| 2024-02-09 | 4 | Moore Yan — Chief Medical Officer | Grant/award (A): 110,000 (derivative) @ $0 | EDGAR |
| 2024-02-09 | 4 | Zeng Ling — See Remarks | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2024-02-09 | 4 | Reed Joshua — Chief Financial Officer | Grant/award (A): 110,000 (derivative) @ $0 | EDGAR |
| 2024-02-09 | 4 | SCHADE CHRISTIAN S — Director | Grant/award (A): 512,848 (derivative) @ $0 | EDGAR |
| 2024-02-09 | 4/A | SCHADE CHRISTIAN S — Director | Grant/award (A): 36,713 (derivative) @ $0 | EDGAR |
| 2023-08-29 | 4 | Werner Michelle C — Director | Grant/award (A): 36,713 (derivative) @ $0 | EDGAR |
| 2023-07-12 | 4 | SCHADE CHRISTIAN S — Director | Grant/award (A): 36,713 (derivative) @ $0 | EDGAR |
| 2023-06-09 | 4 | Levy Elliott M. — Director | Grant/award (A): 18,118 (derivative) @ $0 | EDGAR |
| 2023-06-09 | 4 | Boehm Rainer J. — Director | Grant/award (A): 18,118 (derivative) @ $0 | EDGAR |
| 2023-06-09 | 4 | Young Richard A — Director | Grant/award (A): 18,118 (derivative) @ $0 | EDGAR |
| 2023-06-09 | 4 | Szela Mary T — Director | Grant/award (A): 18,118 (derivative) @ $0 | EDGAR |
| 2023-06-09 | 4 | MENDLEIN JOHN — Director | Grant/award (A): 18,118 (derivative) @ $0 | EDGAR |
| 2023-06-09 | 4 | AFEYAN NOUBAR — Director, 10% owner | Grant/award (A): 18,118 (derivative) @ $0 | EDGAR |
| 2023-06-09 | 4 | BESHAR LUKE M — Director | Grant/award (A): 18,118 (derivative) @ $0 | EDGAR |
| 2023-06-05 | 4 | Young Richard A — Director | Sale (S): 5,000 @ $8 | EDGAR |
| 2023-05-03 | 4 | Young Richard A — Director | Sale (S): 5,000 @ $8 | EDGAR |
| 2023-04-10 | 4 | Young Richard A — Director | Sale (S): 5,000 @ $8 | EDGAR |
| 2023-03-20 | 4 | Young Richard A — Director | Sale (S): 10,000 @ $8 | EDGAR |
| 2023-03-02 | 4 | McManus Kevin — Chief Human Resources Officer | Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2023-03-02 | 4 | Moore Yan — Chief Medical Officer | Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2023-03-02 | 4 | Karande Mahesh — President and CEO, Director | Grant/award (A): 170,000 (derivative) @ $0 | EDGAR |
| 2023-03-02 | 4 | McCauley Thomas — Chief Scientific Officer | Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2023-03-02 | 4 | Zeng Ling — See Remarks | Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2023-03-02 | 4 | Reed Joshua — Chief Financial Officer | Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2023-02-27 | 4 | Flagship Pioneering Inc. — 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC — 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. — 10% owner AFEYAN NOUBAR — Director, 10% owner | Purchase (P): 1,993,986 @ $5.78 · Purchase (P): 1,329,324 @ $5.78 | EDGAR |
| 2023-01-11 | 4 | Young Richard A — Director | Sale (S): 20,000 @ $8 | EDGAR |
| 2022-10-28 | 4 | Karande Mahesh — President and CEO, Director | Grant/award (A): 170,000 (derivative) @ $0 | EDGAR |
| 2022-10-28 | 4 | McCauley Thomas — Chief Scientific Officer | Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2022-10-28 | 4 | McManus Kevin — Chief Human Resources Officer | Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2022-10-28 | 4 | Moore Yan — Chief Medical Officer | Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2022-10-28 | 4 | Zeng Ling — See Remarks | Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2022-10-28 | 4 | Reed Joshua — Chief Financial Officer | Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2022-09-15 | 4 | Young Richard A — Director | Sale (S): 10,000 @ $8 | EDGAR |
| 2022-09-01 | 4 | Boehm Rainer J. — Director | Grant/award (A): 36,713 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | BESHAR LUKE M — Director | Grant/award (A): 18,118 (derivative) @ $0 | EDGAR |
Recent 8-K events — Omega Therapeutics, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2025-02-24 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2025-02-14 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.03 — Bankruptcy or Receivership 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | EDGAR |
| 2025-02-03 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events | EDGAR |
| 2025-01-28 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2025-01-17 | 8-K | 2.04 — Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement | EDGAR |
| 2025-01-10 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2024-12-31 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events | EDGAR |
| 2024-12-06 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2024-11-14 | 8-K | 1.01 — Entry into a Material Definitive Agreement 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-10-04 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=OMGA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs